Vol 10, No 2 (2019)
Case report
Published online: 2019-10-16

open access

Page views 421
Article views/downloads 360
Get Citation

Connect on Social Media

Connect on Social Media

The role of brentuximab vedotin in the treatment of patients with refractory/relapsed Hodgkin lymphoma based on two case reports

Monika Chełstowska1, Krzysztof Jamroziak1, Ewa Lech-Marańda1, Krzysztof Warzocha1
DOI: 10.5603/Hem.2019.0024
Hematologia 2019;10(2):95-104.

Abstract

Hodgkin lymphoma (HL) is a form of lymphoma with good prognosis in the majority of patients, who are cured after first line chemotherapy. However, in about 25–30% of patients, the course of the disease is unfavorable and patients require treatment of subsequent lines. In further treatment, intensive polychemotherapy is used, consolidated with hematopoietic stem cell transplantation (autologous or allogenic). Also new drugs are wanted. Immunotherapy is promising, including antibodies against CD30 — brentuximab vedotin, and antibodies, that affect the PD1/PD-L1 and PD-L2 pathways — nivolumab, pembrolizumab. Determining the optimal management of patients with relapse and refractory HL requires further investigation.

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice